CLINICAL TRIALS PROFILE FOR ILLUCCIX
✉ Email this page to a colleague
All Clinical Trials for ILLUCCIX
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT05558956 ↗ | Total Body PET-CT Imaging of Prostate Cancer Using Illuccix | Not yet recruiting | Telix International Pty Ltd | Early Phase 1 | 2022-10-01 | Illuccix will be used per the prescribing instructions for PET-CT imaging on the United Imaging scanner uEXPLORER to establish a standard scanning protocol. |
| NCT05558956 ↗ | Total Body PET-CT Imaging of Prostate Cancer Using Illuccix | Not yet recruiting | BAMF Health | Early Phase 1 | 2022-10-01 | Illuccix will be used per the prescribing instructions for PET-CT imaging on the United Imaging scanner uEXPLORER to establish a standard scanning protocol. |
| NCT05847348 ↗ | 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients | Not yet recruiting | Grand Pharmaceutical (China) Co., Ltd. | Phase 3 | 2023-06-30 | This is a prospective, open-label, single-arm, multicenter bridging study in Chinese patients with prostate cancer. This multicenter study is planned to be conducted in patients with biochemical recurrence (BCR) of elevated PSA after radical prostatectomy or radical radiotherapy. This study investigates how well 68Ga-PSMA-11 PET/CT works in detecting BCR prostate cancer in Chinese patient. 68Ga-PSMA-11, developed by Telix, is a new molecular entity tracer with the trade name Illuccix®, which is approved by FDA for the examination of: 1) patients with suspected metastatic PC who are scheduled for initial treatment; 2) patients with biochemical recurrence of elevated PSA levels after initial radical radiotherapy. |
| NCT05847348 ↗ | 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients | Not yet recruiting | Telix International Pty Ltd | Phase 3 | 2023-06-30 | This is a prospective, open-label, single-arm, multicenter bridging study in Chinese patients with prostate cancer. This multicenter study is planned to be conducted in patients with biochemical recurrence (BCR) of elevated PSA after radical prostatectomy or radical radiotherapy. This study investigates how well 68Ga-PSMA-11 PET/CT works in detecting BCR prostate cancer in Chinese patient. 68Ga-PSMA-11, developed by Telix, is a new molecular entity tracer with the trade name Illuccix®, which is approved by FDA for the examination of: 1) patients with suspected metastatic PC who are scheduled for initial treatment; 2) patients with biochemical recurrence of elevated PSA levels after initial radical radiotherapy. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ILLUCCIX
Condition Name
| Condition Name for ILLUCCIX | |
| Intervention | Trials |
| Metastatic Castration-resistant Prostate Cancer | 1 |
| Prostate Cancer | 1 |
| BCR Prostate Carcinoma | 1 |
| Biochemical Recurrence of Malignant Neoplasm of Prostate | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for ILLUCCIX
Trials by Country
Clinical Trial Progress for ILLUCCIX
Clinical Trial Phase
Clinical Trial Sponsors for ILLUCCIX
Sponsor Name
